{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:52:07Z","timestamp":1792572727952,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.diagmicrobio.2022.115713","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:34:19Z","timestamp":1650627259000},"page":"115713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020"],"prefix":"10.1016","volume":"103","author":[{"given":"Leonard R.","family":"Duncan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal A.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diagmicrobio.2022.115713_bib0001","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7861\/clinmedicine.18-2-150","article-title":"Bone and joint infection","volume":"18","author":"Colston","year":"2018","journal-title":"Clin Med (Lond)"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2022.115713_bib0002","doi-asserted-by":"crossref","first-page":"ofz181","DOI":"10.1093\/ofid\/ofz181","article-title":"The history of antibiotic treatment of osteomyelitis","volume":"6","author":"Cortes-Penfield","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2022.115713_bib0003","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jac\/dkh191","article-title":"Antibiotic treatment of gram-positive bone and joint infections","volume":"53","author":"Darley","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2022.115713_bib0004","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2106\/JBJS.N.01350","article-title":"Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009","volume":"97","author":"Kremers","year":"2015","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2022.115713_bib0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.idc.2017.01.010","article-title":"Osteomyelitis","volume":"31","author":"Schmitt","year":"2017","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2022.115713_bib0006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1055\/s-0033-1364102","article-title":"Organism profile in periprosthetic joint infection: pathogens differ at two arthroplasty infection referral centers in Europe and in the United States","volume":"27","author":"Aggarwal","year":"2014","journal-title":"J Knee Surg"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2022.115713_bib0007","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2022.115713_bib0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10096-012-1807-3","article-title":"Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review","volume":"32","author":"Vardakas","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2022.115713_bib0009","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/BPO.0000000000000439","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus musculoskeletal infections: emerging trends over the past decade","volume":"36","author":"Sarkissian","year":"2016","journal-title":"J Pediatr Orthop"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2022.115713_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2022.115713_bib0011","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijantimicag.2019.01.007","article-title":"Short- versus long-course antibiotics in osteomyelitis: a systematic review and meta-analysis","volume":"53","author":"Huang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2022.115713_bib0012","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2022.115713_bib0013","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.02465-14","article-title":"Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2022.115713_bib0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2022.115713_bib0015","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.diagmicrobio.2010.10.032","article-title":"In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study","volume":"69","author":"Walkty","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2022.115713_bib0016","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2019.01.015","article-title":"Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017)","volume":"94","author":"Pfaller","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2022.115713_bib0017","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2022.115713_bib0018","doi-asserted-by":"crossref","first-page":"e01566","DOI":"10.1128\/AAC.01566-18","article-title":"Ceftobiprole activity against Gram-positive and -negative pathogens collected from the United States in 2006 and 2016","volume":"63","author":"Pfaller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2022.115713_bib0019","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115713_bib0020","first-page":"4565","article-title":"Ceftobiprole for the treatment of pneumonia: a European perspective","volume":"9","author":"Liapikou","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"13","key":"10.1016\/j.diagmicrobio.2022.115713_bib0021","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s40265-014-0273-x","article-title":"Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia","volume":"74","author":"Syed","year":"2014","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2022.115713_bib0022","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/antibiotics10020170","article-title":"Ceftobiprole perspective: Current and potential future indications","volume":"10","author":"Lupia","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2022.115713_bib0023","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2022.115713_bib0024","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115713_bib0025","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jgar.2020.03.010","article-title":"Real-life experience with ceftobiprole in a tertiary-care hospital","volume":"22","author":"Durante-Mangoni","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2022.115713_bib0026","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","article-title":"Ceftobiprole: drug evaluation and place in therapy","volume":"17","author":"Giacobbe","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2022.115713_bib0027","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.diagmicrobio.2018.01.010","article-title":"Activity of ceftobiprole against Staphylococcus spec. isolates derived from foreign body associated infections","volume":"91","author":"Hischebeth","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2022.115713_bib0028","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diagmicrobio.2007.02.010","article-title":"In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection","volume":"58","author":"Rouse","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2022.115713_bib0029","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jgar.2018.01.022","article-title":"In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections","volume":"13","author":"Isnard","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2022.115713_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12941-020-00351-5","article-title":"Ceftobiprole: A potential empirical post-operative monotherapy in prosthetic joint infections","volume":"19","author":"Duployez","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2022.115713_bib0031","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1128\/AAC.00926-12","article-title":"Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits","volume":"56","author":"Saleh-Mghir","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2022.115713_bib0032","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1128\/AAC.00638-07","article-title":"Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus","volume":"52","author":"Yin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2022.115713_bib0033","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/AAC.49.9.3789-3793.2005","article-title":"Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus","volume":"49","author":"Vaudaux","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2022.115713_bib0034","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijantimicag.2013.09.013","article-title":"Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays","volume":"43","author":"Abbanat","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2022.115713_bib0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1155\/2010\/296760","article-title":"Ceftobiprole: First reported experience in osteomyelitis","volume":"21","author":"Macdonald","year":"2010","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.diagmicrobio.2022.115713_bib0036","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jgar.2021.01.014","article-title":"Real-life experience with ceftobiprole in Canada: results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry","volume":"24","author":"Zhanel","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2022.115713_bib0037","series-title":"M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: eleventh edition","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2022.115713_bib0038","series-title":"M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st edition","year":"2021"},{"key":"10.1016\/j.diagmicrobio.2022.115713_bib0039","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","year":"2021"},{"key":"10.1016\/j.diagmicrobio.2022.115713_bib0040","unstructured":"Tygacil. Tygacil \u00ae package insert. 2018; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211158s000lbl.pdf."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889322000797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889322000797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:57:14Z","timestamp":1760003834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889322000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0732889322000797"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115713","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115713"}}